Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR.

爱尔康（SIX/NYSE: ALC），全球眼保健领域的领导者，致力于帮助人们获得清晰视力，与LENSAR公司（NASDAQ: LNSR），一家专注于白内障治疗先进激光解决方案的全球医疗技术公司，今天宣布双方已达成一项最终合并协议，根据该协议，爱尔康计划收购LENSAR。

The acquisition includes ALLY Robotic Cataract Laser Treatment System™, LENSAR’s proprietary Streamline.

收购内容包括ALLY机器人白内障激光治疗系统™ 和LENSAR专有的Streamline。

software technology and LENSAR legacy laser system, building Alcon’s femtosecond laser-assisted cataract surgery (FLACS) offering.

软件技术和LENSAR传统激光系统，构建了Alcon的飞秒激光辅助白内障手术（FLACS）产品。

Under the terms of the agreement, Alcon will purchase all outstanding shares of LENSAR for $14.00 per share in cash (an aggregate implied value of approximately $356 million

根据协议条款，爱尔康将按每股14.00美元的价格收购LENSAR的所有已发行股份，总价约为3.56亿美元。

), with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR’s products between January 1, 2026, and December 31, 2027. The total potential consideration of $16.75 per share represents a premium of 24% to LENSAR’s 30-day VWAP and a premium of 47% to LENSAR’s 90-day VWAP, assuming the milestone is met.

），此外还包含一项不可交易的或有价值权，每股最多可获得2.75美元现金，条件是LENASR的产品在2026年1月1日至2027年12月31日期间累计完成614,000例手术。若达到该里程碑，每股总计16.75美元的潜在总对价较LENASR的30天成交量加权平均价格（VWAP）溢价24%，较LENASR的90天VWAP溢价47%。

The transaction represents a total consideration of up to approximately $430 million.

该交易的总对价高达约4.3亿美元。

“We are excited for the opportunity to bring LENSAR’s unique next-generation technologies and intellectual property into our innovative, market-leading equipment portfolio,” said David Endicott, Chief Executive Officer of Alcon. “By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery.”.

“我们很高兴有机会将LENSAR独特的下一代技术和知识产权纳入我们创新的、市场领先的设备组合，”爱尔康首席执行官David Endicott表示。“通过利用我们的全球布局，我们有机会将先进的飞秒激光技术的好处带给全世界更多的外科医生，并继续提高白内障手术的效率。”

Currently, there are more than 5 million cataract procedures in the U.S., and approximately 32 million globally.

目前，美国有超过500万例白内障手术，全球大约有3200万例。

FLACS is designed to allow surgeons to utilize a computer-guided laser to address and manage the high prevalence of visually significant astigmatism, perform corneal incisions, capsulotomy, including a refractive capsulotomy, and lens fragmentation, removing the need for blade incisions.

FLACS旨在让外科医生利用计算机引导的激光来处理和管理高发的视觉显著性散光，进行角膜切口、囊切开术（包括屈光性囊切开术）以及晶状体碎裂，从而无需使用刀片切口。

This can contribute to more precise, reproducible and reliable cataract surgery..

这有助于实现更精确、可重复和可靠的白内障手术。

* Assuming use of the Treasury Stock Method

* 假设使用库存股法

“Our focus has been on providing surgeons with breakthrough laser technology in cataract surgery for today and tomorrow,” said Nick Curtis, Chief Executive Officer of LENSAR. “Thanks to the continued passion and commitment of LENSAR associates, customers and our investors, we are excited about the potential Alcon has to advance the industry in next-generation laser technology for refractive cataract surgery, furthering our and their mission to meet the needs of both surgeons and their cataract patients.”.

“我们的重点一直是为外科医生提供当今和未来白内障手术的突破性激光技术，”LENSAR 首席执行官 Nick Curtis 表示。“由于 LENSAR 员工、客户以及投资者持续的热情与奉献，我们对 Alcon 在推动下一代屈光性白内障手术激光技术方面充满期待，这也进一步实现了我们及他们的使命，即满足外科医生及其白内障患者的需求。”

The transaction is anticipated to close in mid-to-late 2025, subject to customary closing conditions, including regulatory approval and approval by LENSAR’s stockholders.

该交易预计将在2025年年中至年末完成，但须符合惯例的交割条件，包括监管机构的批准以及LENSAR股东的批准。

Lazard is serving as financial advisor to Alcon, and Norton Rose Fulbright is serving as legal advisor to Alcon. Wells Fargo is serving as financial advisor to LENSAR and Latham & Watkins LLP is serving as legal advisor to LENSAR.

Lazard担任Alcon的财务顾问，Norton Rose Fulbright担任Alcon的法律顾问。Wells Fargo担任LENSAR的财务顾问，Latham & Watkins LLP担任LENSAR的法律顾问。

About Alcon

关于爱尔康

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors.

爱尔康帮助人们获得卓越的视力。作为拥有75年以上历史的眼科护理全球领导者，我们提供最广泛的产品组合来增强视力并改善人们的生活。我们的外科和视力保健产品每年惠及140多个国家中超过2.6亿受白内障、青光眼、视网膜疾病和屈光不正等问题困扰的人们。

Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at .

我们的25,000多名员工通过创新的产品、与眼科护理专业人士的合作以及提升优质眼科护理可及性的项目，正在改善人们的生活质量。欲了解更多信息，请访问 。

About LENSAR

关于LENSAR

LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software.

LENSAR是一家处于商业化阶段的医疗器械公司，专注于设计、开发和推广用于治疗白内障以及作为手术组成部分管理散光的先进系统。LENSAR开发了其ALLY机器人白内障激光系统™，这是一款紧凑且高度符合人体工程学的系统，采用极快速的双模态激光，并将人工智能集成到专有的成像和软件中。

ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary Streamline.

ALLY 旨在通过利用 LENSAR 的先进机器人技术来革新高端白内障手术，能够在无菌手术室或门诊手术套间中完成整个手术过程，提供操作效率并降低开支。ALLY 包含 LENSAR 专有的 Streamline 技术。